person · Reporting owner

SPRINGER TIMOTHY A

Disclosed activity across 4 companies

Tapewire entity: 39790
SEC CIK: 0001055624

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cartesian Therapeutics, Inc.RNAC · Entity 6015	Director · 10% owner	January 02, 2026	January 06, 2026
Tectonic Therapeutic, Inc.TECX · Entity 5328	Director · 10% owner	June 09, 2026	June 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cartesian Therapeutics, Inc.

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,646,285	Reported balance After 2026-01-02 transaction · row 1 1 source row Row 1 · 2026-01-02 · Grant · Acquired 2,600 · Balance 8,646,285 F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.76 · Expires 2036-01-01	Direct	7,800	Reported balance After 2026-01-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-01-02 · Grant · Acquired 7,800 · Balance 7,800
Common StockSEC Table I · non-derivative	IndirectBy wife	330,695	Reported balance Holding disclosure · report date 2026-01-02 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 330,695
Common StockSEC Table I · non-derivative	IndirectSee Footnote	656,513	Reported balance Holding disclosure · report date 2026-01-02 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 656,513 F2: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.

F2: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.

Tectonic Therapeutic, Inc.

Report date June 09, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.56 · Expires 2036-06-08	Direct	10,200	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 10,200 · Balance 10,200 F1: The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Morphic Holding, Inc.

Report date August 16, 2024 · Filed August 20, 2024

Section 16 reporting ended · disclosed 2024-08-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-08-16 transaction · row 1 1 source row Row 1 · 2024-08-16 · Other · Disposed 4,608,052 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.
Common StockSEC Table I · non-derivative	IndirectSee TAS Partners LLC	Reported balance After 2024-08-16 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2024-08-16 · Other · Disposed 2,768,893 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F3: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares.
Common StockSEC Table I · non-derivative	IndirectBy Spouse	Reported balance After 2024-08-16 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2024-08-16 · Other · Disposed 42,873 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.76 · Expires 2029-04-11	Direct	Reported balance After 2024-08-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-08-16 · Disposition to issuer · Disposed 4,288 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2029-06-26	Direct	Reported balance After 2024-08-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-08-16 · Disposition to issuer · Disposed 24,000 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.72 · Expires 2029-12-05	Direct	Reported balance After 2024-08-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-08-16 · Disposition to issuer · Disposed 90,000 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.96 · Expires 2030-06-18	Direct	Reported balance After 2024-08-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-08-16 · Disposition to issuer · Disposed 12,000 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.79 · Expires 2031-06-16	Direct	Reported balance After 2024-08-16 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-08-16 · Disposition to issuer · Disposed 9,996 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2032-06-08	Direct	Reported balance After 2024-08-16 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-08-16 · Disposition to issuer · Disposed 17,550 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.47 · Expires 2033-05-31	Direct	Reported balance After 2024-08-16 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2024-08-16 · Disposition to issuer · Disposed 12,535 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.52 · Expires 2034-06-03	Direct	Reported balance After 2024-08-16 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2024-08-16 · Disposition to issuer · Disposed 23,168 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.

F3: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares.

F4: The Company Stock Option ("Option") is fully vested.

F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.

F6: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

Scholar Rock Holding Corp

Report date December 10, 2019 · Filed December 12, 2019

Section 16 reporting ended · disclosed 2019-12-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,376,567	Reported balance After 2019-12-10 transaction · row 1 1 source row Row 1 · 2019-12-10 · Gift · Disposed 296,000 · Balance 2,376,567 F1: Represents shares of the Company's common stock transfered as a gift for no consideration to the Institute of Protein Innovation, a not-for-profit research institution.
Common StockSEC Table I · non-derivative	IndirectBy TAS Partners, LLC	580,855	Reported balance Holding disclosure · report date 2019-12-10 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 580,855 F2: Timothy Springer is the Managing Member of TAS Partners LLC.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of the Company's common stock transfered as a gift for no consideration to the Institute of Protein Innovation, a not-for-profit research institution.

F2: Timothy Springer is the Managing Member of TAS Partners LLC.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 18, 2024 Filed Mar 28, 2024 21:11 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	800	$0.61	$488.00	Disclosure SEC source: 0001453687-24-000050 · wk-form4_1711660282.xml · nonDerivative · entry 10 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By wife Disclosed balance after: 104,818 Read SEC document
March 15, 2024 Filed Mar 18, 2024 21:29 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	537,500	$0.59	$314,545.00	Disclosure SEC source: 0001453687-24-000041 · wk-form4_1710797338.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 31,054,362 F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.5326 to $0.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
March 15, 2024 Filed Mar 28, 2024 21:11 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	1,200	$0.56	$672.00	Disclosure SEC source: 0001453687-24-000050 · wk-form4_1711660282.xml · nonDerivative · entry 9 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By wife Disclosed balance after: 104,018 Read SEC document
March 14, 2024 Filed Mar 18, 2024 21:29 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	648,372	$0.54	$351,676.97	Disclosure SEC source: 0001453687-24-000041 · wk-form4_1710797338.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 30,516,862 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.5002 to $0.5600. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
March 14, 2024 Filed Mar 28, 2024 21:11 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	2,000	$0.53	$1,061.00	Disclosure SEC source: 0001453687-24-000050 · wk-form4_1711660282.xml · nonDerivative · entry 8 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By wife Disclosed balance after: 102,818 F6 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.52 to $0.54. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
March 13, 2024 Filed Mar 28, 2024 21:11 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	3,200	$0.58	$1,867.84	Disclosure SEC source: 0001453687-24-000050 · wk-form4_1711660282.xml · nonDerivative · entry 7 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By wife Disclosed balance after: 100,818 F5 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.58 to $0.59. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
March 12, 2024 Filed Mar 28, 2024 21:11 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	1,200	$0.61	$734.64	Disclosure SEC source: 0001453687-24-000050 · wk-form4_1711660282.xml · nonDerivative · entry 6 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By wife Disclosed balance after: 97,618 F4 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.61 to $0.62. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
March 11, 2024 Filed Mar 28, 2024 21:11 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	1,200	$0.65	$784.92	Disclosure SEC source: 0001453687-24-000050 · wk-form4_1711660282.xml · nonDerivative · entry 5 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By wife Disclosed balance after: 96,418 F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.65 to $0.66. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
March 08, 2024 Filed Mar 28, 2024 21:11 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	4,800	$0.66	$3,186.72	Disclosure SEC source: 0001453687-24-000050 · wk-form4_1711660282.xml · nonDerivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By wife Disclosed balance after: 95,218 F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.65 to $0.68. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
February 07, 2024 Filed Mar 28, 2024 21:11 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	2,400	$0.66	$1,575.12	Disclosure SEC source: 0001453687-24-000050 · wk-form4_1711660282.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By wife Disclosed balance after: 90,418 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.65 to $0.67. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
February 06, 2024 Filed Mar 28, 2024 21:11 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	800	$0.65	$520.00	Disclosure SEC source: 0001453687-24-000050 · wk-form4_1711660282.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By wife Disclosed balance after: 88,018 Read SEC document
January 17, 2024 Filed Mar 28, 2024 21:11 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	800	$0.69	$552.00	Disclosure SEC source: 0001453687-24-000050 · wk-form4_1711660282.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By wife Disclosed balance after: 87,218 Read SEC document
January 02, 2024 Filed Jan 4, 2024 22:06 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	GrantStock Option (Right to Buy) · Derivative	228,000	$0.00 Strike: $0.66	$0.00	Disclosure SEC source: 0001453687-24-000022 · wk-form4_1704405968.xml · derivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,000 Underlying: Common Stock · 228,000 shares Expires 2034-01-01 F3 · derivative.exercise_date: This award will vest in 36 equal monthly installments, so that it shall be fully vested on the third anniversary of the date of grant. Read SEC document
January 02, 2024 Filed Jan 4, 2024 22:06 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	GrantCommon Stock	178,000	$0.00	$0.00	Disclosure SEC source: 0001453687-24-000022 · wk-form4_1704405968.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,471,625 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in three equal annual installments so that the underlying shares will be fully vested on January 2, 2027. Read SEC document
November 15, 2023 Filed Nov 15, 2023 22:20 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	GrantSeries A Convertible Preferred Stock	123,925.407	$403.47	$49,999,998.07	Disclosure SEC source: 0001453687-23-000087 · wk-form4_1700086801.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,925.407 Read SEC document
November 15, 2023 Filed Nov 15, 2023 22:20 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	GrantSeries A Convertible Preferred Stock	24,785.081	$403.47	$9,999,999.45	Disclosure SEC source: 0001453687-23-000087 · wk-form4_1700086801.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 24,785.081 F1 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:20 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	75,000	$0.93 Strike: $1.13	$69,750.00	Disclosure SEC source: 0001453687-23-000087 · wk-form4_1700086801.xml · derivative · entry 12 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2033-01-01 F8 · derivative.exercise_date: This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $69,750, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:20 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	40,000	Not disclosed Strike: $3.31	Not disclosed	Disclosure SEC source: 0001453687-23-000087 · wk-form4_1700086801.xml · derivative · entry 11 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2032-01-02 F7 · price: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. F7 · derivative.exercise_date: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:20 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	40,000	Not disclosed Strike: $4.01	Not disclosed	Disclosure SEC source: 0001453687-23-000087 · wk-form4_1700086801.xml · derivative · entry 10 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2031-03-29 F6 · price: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger. F6 · derivative.exercise_date: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:20 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	20,000	Not disclosed Strike: $3.00	Not disclosed	Disclosure SEC source: 0001453687-23-000087 · wk-form4_1700086801.xml · derivative · entry 9 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2030-06-18 F5 · price: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger. F5 · derivative.exercise_date: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:20 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $2.10	Not disclosed	Disclosure SEC source: 0001453687-23-000087 · wk-form4_1700086801.xml · derivative · entry 8 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-06-13 F4 · price: This option, which provided for vesting in full on June 14, 2020, was canceled in the Merger. F4 · derivative.exercise_date: This option, which provided for vesting in full on June 14, 2020, was canceled in the Merger. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:20 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $12.75	Not disclosed	Disclosure SEC source: 0001453687-23-000087 · wk-form4_1700086801.xml · derivative · entry 7 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-06-14 F3 · price: This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger. F3 · derivative.exercise_date: This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger. Read SEC document
November 13, 2023 Filed Nov 15, 2023 22:20 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	Disposition to issuerStock Option (Right to Buy) · Derivative	6,410	Not disclosed Strike: $17.47	Not disclosed	Disclosure SEC source: 0001453687-23-000087 · wk-form4_1700086801.xml · derivative · entry 6 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,410 shares Expires 2027-06-15 F2 · price: This option, which provided for vesting in full on June 14, 2018, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. F2 · derivative.exercise_date: This option, which provided for vesting in full on June 14, 2018, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. Read SEC document
June 28, 2023 Filed Jun 30, 2023 23:03 UTC	Morphic Holding, Inc. MORF · Entity 88114	OtherCommon Stock	429	$0.00	$0.00	Disclosure SEC source: 0001209191-23-040388 · doc4.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 2,768,893 F1 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by PMC VII. F2 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
June 28, 2023 Filed Jun 30, 2023 23:03 UTC	Morphic Holding, Inc. MORF · Entity 88114	OtherCommon Stock	429	$0.00	$0.00	Disclosure SEC source: 0001209191-23-040388 · doc4.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,608,052 F1 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by PMC VII. Read SEC document
June 01, 2023 Filed Jun 2, 2023 23:02 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantDirector Stock Option (Right to Buy) · Derivative	12,535	$0.00 Strike: $56.47	$0.00	Disclosure SEC source: 0001209191-23-034035 · doc4.xml · derivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,535 Underlying: Common Stock · 12,535 shares Expires 2033-05-31 F1 · derivative.exercise_date: The option will vest in full on the earlier of (a) June 1, 2024 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document
May 03, 2023 Filed May 4, 2023 23:06 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	1,050,000	$45.00	$47,250,000.00	Disclosure SEC source: 0001209191-23-027477 · doc4.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 2,768,464 F1 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
February 13, 2023 Filed Feb 13, 2023 21:14 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantCommon Stock	806,223	$35.35	$28,499,983.05	Disclosure SEC source: 0001209191-23-008699 · doc4.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 1,718,464 F1 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
February 13, 2023 Filed Feb 13, 2023 21:14 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantCommon Stock	42,432	$35.35	$1,499,971.20	Disclosure SEC source: 0001209191-23-008699 · doc4.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,607,623 Read SEC document
January 02, 2023 Filed Jan 4, 2023 21:59 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	GrantStock Option (Right to Buy) · Derivative	75,000	$0.00 Strike: $1.13	$0.00	Disclosure SEC source: 0001453687-23-000016 · wf-form4_167286954984675.xml · derivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-01 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 2, 2024. Read SEC document
June 08, 2022 Filed Jun 10, 2022 23:00 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantDirector Stock Option (Right to Buy) · Derivative	17,550	$0.00 Strike: $24.49	$0.00	Disclosure SEC source: 0001209191-22-036115 · doc4.xml · derivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,550 Underlying: Common Stock · 17,550 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option will vest in full on the earlier of (a) June 8, 2023 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document
April 11, 2022 Filed Apr 14, 2022 01:07 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	GrantWarrant (right to buy) · Derivative	5,011,200	Not disclosed Strike: $1.55	Not disclosed	Disclosure SEC source: 0001453687-22-000057 · wf-form4_164989842475165.xml · derivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,011,200 Underlying: Common Stock · 5,011,200 shares Expires 2027-04-11 F1 · price: Each share of common stock and accompanying warrant to purchase 0.75 shares of common stock was purchased at a combined ofering price of $1.41. The shares of common stock and accompanying warrants were acquired by the reporting person as units, but were issued separately and were immediately separable upon issuance. F2 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
April 11, 2022 Filed Apr 14, 2022 01:07 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	6,681,600	Not disclosed	Not disclosed	Disclosure SEC source: 0001453687-22-000057 · wf-form4_164989842475165.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 29,868,490 F1 · price: Each share of common stock and accompanying warrant to purchase 0.75 shares of common stock was purchased at a combined ofering price of $1.41. The shares of common stock and accompanying warrants were acquired by the reporting person as units, but were issued separately and were immediately separable upon issuance. F2 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
January 03, 2022 Filed Jan 5, 2022 21:35 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $3.31	$0.00	Disclosure SEC source: 0001453687-22-000023 · wf-form4_164141850647692.xml · derivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 3, 2023. Read SEC document
December 15, 2021 Filed Dec 17, 2021 21:36 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	211,190	$2.99	$631,099.08	Disclosure SEC source: 0001453687-21-000188 · wf-form4_163977694300882.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 23,186,890 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.95 to $3.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
December 13, 2021 Filed Dec 13, 2021 22:16 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	14,592	$2.98	$43,491.46	Disclosure SEC source: 0001453687-21-000178 · wf-form4_163943377202254.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,975,700 F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.9698 to $3.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F1 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
December 10, 2021 Filed Dec 13, 2021 22:16 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	58,681	$2.99	$175,438.59	Disclosure SEC source: 0001453687-21-000178 · wf-form4_163943377202254.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,961,108 F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.94 to $3.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F1 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
December 09, 2021 Filed Dec 13, 2021 22:16 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	3,748,000	$3.06	$11,468,880.00	Disclosure SEC source: 0001453687-21-000178 · wf-form4_163943377202254.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,902,427 F1 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
August 20, 2021 Filed Aug 20, 2021 23:08 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	11,511	$56.80	$653,838.61	Disclosure SEC source: 0001209191-21-052853 · doc4.xml · nonDerivative · entry 7 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 912,241 F8 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $56.44 to $57.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
August 20, 2021 Filed Aug 20, 2021 23:08 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	109	$56.01	$6,104.97	Disclosure SEC source: 0001209191-21-052853 · doc4.xml · nonDerivative · entry 6 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 900,730 F7 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $55.275 to $56.075 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
August 19, 2021 Filed Aug 20, 2021 23:08 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	13,874	$56.82	$788,338.72	Disclosure SEC source: 0001209191-21-052853 · doc4.xml · nonDerivative · entry 5 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 900,621 F6 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $56.57 to $57.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
August 19, 2021 Filed Aug 20, 2021 23:08 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	18,916	$56.31	$1,065,182.66	Disclosure SEC source: 0001209191-21-052853 · doc4.xml · nonDerivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 886,747 F5 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $55.57 to $56.5628 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
August 19, 2021 Filed Aug 20, 2021 23:08 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	210	$54.71	$11,488.20	Disclosure SEC source: 0001209191-21-052853 · doc4.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 867,831 F4 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $54.42 to $54.85 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
August 18, 2021 Filed Aug 20, 2021 23:08 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	9,208	$56.35	$518,845.02	Disclosure SEC source: 0001209191-21-052853 · doc4.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 867,621 F3 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $56.095 to $56.64 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
August 18, 2021 Filed Aug 20, 2021 23:08 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	21,099	$55.42	$1,169,357.22	Disclosure SEC source: 0001209191-21-052853 · doc4.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 858,413 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $55.09 to $56.08 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document
June 16, 2021 Filed Jun 17, 2021 23:17 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantDirector Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $64.79	$0.00	Disclosure SEC source: 0001209191-21-041698 · doc4.xml · derivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-06-16 F1 · derivative.exercise_date: The option will vest in full on the earlier of (a) June 16, 2022 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document
June 16, 2021 Filed Apr 29, 2022 20:21 UTC Amendment	Morphic Holding, Inc. MORF · Entity 88114	GrantDirector Stock Option (right to buy) · Derivative	9,996	$0.00 Strike: $64.79	$0.00	Disclosure SEC source: 0001209191-22-026246 · doc4a.xml · derivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,996 Underlying: Common Stock · 9,996 shares Expires 2031-06-16 F1 · shares: This Form 4 is being amended to reflect the amount actually granted, as the originally reported share number was in error. F2 · derivative.exercise_date: The option will vest in full on the earlier of (a) June 16, 2022 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document
May 26, 2021 Filed May 26, 2021 23:02 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	2,413	$47.36	$114,285.23	Disclosure SEC source: 0001209191-21-036038 · doc4.xml · nonDerivative · entry 7 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 837,314 F8 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $47.24 to $47.67 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
May 26, 2021 Filed May 26, 2021 23:02 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	22,587	$46.93	$1,060,014.69	Disclosure SEC source: 0001209191-21-036038 · doc4.xml · nonDerivative · entry 6 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners LLC Disclosed balance after: 834,901 F7 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $46.22 to $47.215 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
May 26, 2021 Filed May 26, 2021 21:21 UTC	Cartesian Therapeutics, Inc. SELB · Entity 6015	PurchaseCommon Stock	926,170	$4.00	$3,705,698.79	Disclosure SEC source: 0001453687-21-000076 · wf-form4_162206406933869.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 19,154,427 F4 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $3.83 to $4.15. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held by TAS Partners LLC. The Reporting Person is the managing member of TAS Partners LLC. The Reporting Person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.